Group again petitions FDA to ban Novo Nordisk's Victoza

Save

While Victoza brought in more than $2 billion last year, it has been dogged by concerns that it raises the risk of pancreatitis–and despite it and other similar drugs being cleared by reviews by both the FDA and EU regulators this year, some keep pushing the FDA to consider pulling it off the market.